NeuroEPO

DRUG8 trials

Conditions

Mild Alzheimer's DiseaseMild to moderate Alzheimer'sModerate Alzheimer's DiseaseParkinson DiseaseParkinson's disease stage II-IIISTROKE Ischemic strokeSpinocerebellar Ataxiamild-moderate Alzheimers disease

Phase 1

Tolerance to NeuroEPO in Parkinson Disease

CompletedNCT04110678

International Center for Neurological Restoration, CubaParkinson Disease

Start: 2015-11-01End: 2017-01-01Updated: 2020-07-15

Phase 2

NeuroEPO in stroke

Active, not recruitingRPCEC00000282

Center of Molecular Immunology (CIM)STROKE Ischemic stroke

Start: 2022-04-10Target: 130Updated: 2026-10-05

Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease

Not yet recruitingNCT07178678

University of SaskatchewanMild Alzheimer's Disease, Moderate Alzheimer's Disease

Start: 2025-11-30End: 2030-12-31Target: 90Updated: 2025-09-17

Phase 3

NeuroEPO in patients with Parkinson disease stage II-III

Active, not recruitingRPCEC00000233

Center of Molecular Immunology (CIM)Parkinson's disease stage II-III

Start: 2017-12-08Target: 102Updated: 2026-10-05

NeuroEPO in patients with Mild-Moderate Alzheimer's disease

Active, not recruitingRPCEC00000232

Center of Molecular Immunology (CIM)Mild to moderate Alzheimer's

Start: 2017-12-11Target: 174Updated: 2026-10-05

NeuroEPO-Ataxia-Adults-Phase III

Active, not recruitingRPCEC00000343

Center of Molecular Immunology (CIM)Spinocerebellar Ataxia

Start: 2021-03-01Target: 80Updated: 2026-10-05

Phase 4

NeuroEPO in mild-moderate Alzheimer's disease amnesic variant

Active, not recruitingRPCEC00000410

Center of Molecular Immunology (CIM)mild-moderate Alzheimers disease

Start: 2022-10-17Target: 1456Updated: 2026-10-05

Unknown Phase

Expanded clinical use of NeuralCIM in mild to moderate Alzheimer's disease (REAL study)

RecruitingRPCEC00000484

Center for Molecular Immunology (CIM)mild-moderate Alzheimers disease -

Start: 2026-09-14Updated: 2026-10-05

Alzheimer s Research & Therapy2023-12-1315 citations

The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity

Frontiers in Neuroscience2022-06-3010 citations

Short-term Tolerance of Nasally-administered NeuroEPO in Patients with Parkinson Disease.

2021-01-3011 citations

Cognitive follow-up six and nine months after intervention with NeuroEPO in Cuban Parkison's patients

2019-11-07